Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia

N/ASuspendedNCT00197483

Hamamatsu University20 enrolled

Overview

Dopamine has been closely associated with prefrontal function. The hypothesis that a lower dopaminergic activity is associated with negative symptoms and cognitive dysfunction observed in the patients of schizophrenia is of a heuristic value in guiding research in this area. This hypothesis led us to test whether pergolide, a D1/D2 agonist, could improve negative symptoms and cognitive impairments prevailing in most patients with schizophrenia. This double-blind placebo controlled study will investigate the remedial effect of pergolide on negative symptoms and cognitive impairments in schizophrenia.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Schizophrenia Negative Symptoms Cognitive Impairments

Interventions

Pergolide (drug)DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients * Were age 18-50 years, met the DSM-IV criteria for schizophrenia * Were treated with a stable dose of risperidone, raging 2 to 6mg, for more than 8 weeks * Had a score ≥15 on negative subscale items in Positive and Negative Syndrome Scale (PANSS) * Had a minimum period of symptom stability, defined as no more than 20% change on consecutive ratings on PANSS for at lease 4 weeks Exclusion Criteria: * Had a history of medical condition or drug treatment that may have affected cognitive performance * Had a history of other psychiatric disorders

Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia

Overview

Conditions

Interventions

Eligibility

Locations (1)